We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Hutchmed (china) Limited | LSE:HCM | London | Ordinary Share | KYG4672N1198 | ORD USD0.10 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 5.00 | 1.62% | 313.00 | 313.00 | 314.00 | 318.00 | 310.00 | 317.00 | 71,836 | 15:15:29 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 838M | 100.78M | - | N/A | 0 |
From May 2019 to May 2024
TIDMHCM
RNS Number : 9126Z
Hutchison China Meditech Limited
20 March 2017
Directors' Share Dealing
London: Monday, March 20, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notifications that:-
1. Mr Paul Carter, Independent Non-executive Director, purchased a total of 2,800 ordinary shares of US$1.00 each in the capital of Chi-Med ("Ordinary Shares") at a price of GBP26.37 per share on March 15, 2017;
2. Dr Dan Eldar, Non-executive Director, purchased a total of 6,225 American Depositary Shares of the Company ("ADSs", each representing one half of one Ordinary Share) at an average price of US$16.85 per ADS on March 15, 2017;
3. Dr Karen Ferrante, Independent Non-executive Director, purchased a total of 2,540 ADSs at an average price of US$19.77 per ADS on March 16, 2017; and
4. Ms Edith Shih, Non-executive Director and Company Secretary, purchased a total of 10,000 ADSs at an average price of US$19.10 per ADS on March 16, 2017.
Following the above purchases, Mr Carter is interested in 2,800 Ordinary Shares, representing approximately 0.005% of the current issued share capital of Chi-Med; Dr Eldar is interested in 6,225 ADSs, representing approximately 0.005% of the current issued share capital of Chi-Med; Dr Ferrante is interested in 2,540 ADSs, representing approximately 0.002% of the current issued share capital of Chi-Med; and Ms Shih is interested in
50,741 ADSs and 60,000 Ordinary Shares, representing approximately 0.14% of the current issued share capital of Chi-Med.
The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.
Hot Features
Premium
1 Details of the person discharging managerial responsibilities/person closely associated
---- ---------------------------------------------------------------------------------------------
a) Name Mr Paul Carter
---- ------------------------------------------- ------------------------------------------------
2 Reason for the notification
---- ---------------------------------------------------------------------------------------------
a) Position/status Independent Non-executive Director
---- ------------------------------------------- ------------------------------------------------
b) Initial notification/Amendment Initial notification
---- ------------------------------------------- ------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
---- ---------------------------------------------------------------------------------------------
a) Name Hutchison China MediTech Limited
---- ------------------------------------------- ------------------------------------------------
b) LEI N/A
---- ------------------------------------------- ------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
---- ----------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of Ordinary Share of US$1.00 each
instrument DI ISIN: KYG4672N1016
Identification code ADS ISIN: US44842L1035
---- ------------------------------------------------------- -------------------------------------------------------
b) Nature of the transaction Acquisition of 2,800 Ordinary Shares on March 15,
2017 at a price of GBP26.37 per share
---- ------------------------------------------------------- -------------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
---------- ----------
GBP26.37 2,800
---------- ----------
---- ------------------------------------------------------- -------------------------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
---- ------------------------------------------------------- -------------------------------------------------------
e) Date of the transaction 2017-03-15
---- ------------------------------------------------------- -------------------------------------------------------
f) Place of the transaction London Stock Exchange (XLON)
---- ------------------------------------------------------- -------------------------------------------------------
1 Details of the person discharging managerial responsibilities/person closely associated
---- -----------------------------------------------------------------------------------------------
a) Name Dr Dan Eldar
---- ---------------------------------------------- -----------------------------------------------
2 Reason for the notification
---- -----------------------------------------------------------------------------------------------
a) Position/status Non-executive Director
---- ---------------------------------------------- -----------------------------------------------
b) Initial notification/Amendment Initial notification
---- ---------------------------------------------- -----------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
---- -----------------------------------------------------------------------------------------------
a) Name Hutchison China MediTech Limited
---- ---------------------------------------------- -----------------------------------------------
b) LEI N/A
---- ---------------------------------------------- -----------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
---- -----------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of ADS each representing one half of one Ordinary Share
instrument of US$1.00
Identification code ADS ISIN: US44842L1035
---- ------------------------------------------------------- -------------------------------------------------------
b) Nature of the transaction Acquisition of 6,225 ADSs on March 15, 2017 at an
average price of US$16.85 per ADS
---- ------------------------------------------------------- -------------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
---------- ----------
US$16.51 3,220
---------- ----------
US$17.19 2,600
---------- ----------
US$17.33 5
---------- ----------
US$17.16 100
---------- ----------
US$17.47 100
---------- ----------
US$17.48 200
---------- ----------
---- ------------------------------------------------------- -------------------------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
---- ------------------------------------------------------- -------------------------------------------------------
e) Date of the transaction 2017-03-15
---- ------------------------------------------------------- -------------------------------------------------------
f) Place of the transaction Nasdaq Stock Market
---- ------------------------------------------------------- -------------------------------------------------------
1 Details of the person discharging managerial responsibilities/person closely associated
---- -----------------------------------------------------------------------------------------------
a) Name Dr Karen Ferrante
---- -------------------------------------------- -------------------------------------------------
2 Reason for the notification
---- -----------------------------------------------------------------------------------------------
a) Position/status Independent Non-executive Director
---- -------------------------------------------- -------------------------------------------------
b) Initial notification/Amendment Initial notification
---- -------------------------------------------- -------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
---- -----------------------------------------------------------------------------------------------
a) Name Hutchison China MediTech Limited
---- -------------------------------------------- -------------------------------------------------
b) LEI N/A
---- -------------------------------------------- -------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
---- -----------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of ADS each representing one half of one Ordinary Share
instrument of US$1.00
Identification code ADS ISIN: US44842L1035
---- ------------------------------------------------------- -------------------------------------------------------
b) Nature of the transaction Acquisition of 2,540 ADSs on March 16, 2017 at an
average price of US$19.77 per ADS
---- ------------------------------------------------------- -------------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
---------- ----------
US$19.76 1,100
---------- ----------
US$19.84 668
---------- ----------
US$19.65 372
---------- ----------
US$19.85 200
---------- ----------
US$19.60 100
---------- ----------
US$19.84 100
---------- ----------
---- ------------------------------------------------------- -------------------------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
---- ------------------------------------------------------- -------------------------------------------------------
e) Date of the transaction 2017-03-16
---- ------------------------------------------------------- -------------------------------------------------------
f) Place of the transaction Nasdaq Stock Market
---- ------------------------------------------------------- -------------------------------------------------------
1 Details of the person discharging managerial responsibilities/person closely associated
---- -----------------------------------------------------------------------------------------------
a) Name Ms Edith Shih
---- --------------------------------------- ------------------------------------------------------
2 Reason for the notification
---- -----------------------------------------------------------------------------------------------
a) Position/status Non-executive Director and Company Secretary
---- --------------------------------------- ------------------------------------------------------
b) Initial notification/Amendment Initial notification
---- --------------------------------------- ------------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
---- -----------------------------------------------------------------------------------------------
a) Name Hutchison China MediTech Limited
---- --------------------------------------- ------------------------------------------------------
b) LEI N/A
---- --------------------------------------- ------------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
---- -----------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of ADS each representing one half of one Ordinary Share
instrument of US$1.00
Identification code ADS ISIN: US44842L1035
---- ------------------------------------------------------- -------------------------------------------------------
b) Nature of the transaction Acquisition of 10,000 ADSs on March 16, 2017 at an
average price of US$19.10 per ADS
---- ------------------------------------------------------- -------------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
---------- ----------
US$19.10 9,908
---------- ----------
US$19.02 92
---------- ----------
---- ------------------------------------------------------- -------------------------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
---- ------------------------------------------------------- -------------------------------------------------------
e) Date of the transaction 2017-03-16
---- ------------------------------------------------------- -------------------------------------------------------
f) Place of the transaction Nasdaq Stock Market
---- ------------------------------------------------------- -------------------------------------------------------
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.
Contacts
Investor Enquiries Christian Hogg, CEO +852 2121 8200 U.K. & International Media Enquiries Anthony Carlisle, +44 7973 611 888 (Mobile) anthony.carlisle@cdrconsultancy.co.uk Citigate Dewe Rogerson U.S. Based Media Enquiries Brad Miles, BMC Communications +1 (917) 570 7340 (Mobile) bmiles@bmccommunications.com Susan Duffy, BMC Communications +1 (917) 499 8887 (Mobile) sduffy@bmccommunications.com Investor Relations Matt Beck, The Trout Group +1 (917) 415 1750 (Mobile) mbeck@troutgroup.com David Dible, +44 7967 566 919 (Mobile) david.dible@citigatedr.co.uk Citigate Dewe Rogerson Panmure Gordon (UK) Limited Richard Gray / Andrew Potts +44 (20) 7886 2500
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHLIFITVIIIFID
(END) Dow Jones Newswires
March 20, 2017 04:04 ET (08:04 GMT)
1 Year Hutchmed (china) Chart |
1 Month Hutchmed (china) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
